ID   NCI-N87 HR
AC   CVCL_WH01
SY   NCI N87 HR
DR   cancercelllines; CVCL_WH01
DR   Wikidata; Q95993868
RX   PubMed=26919099;
CC   Doubling time: 26 hours (PubMed=26919099).
CC   Selected for resistance to: DrugBank; DB00072; Trastuzumab (Herceptin).
CC   Sequence variation: Gene deletion; HGNC; HGNC:6770; SMAD4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C5473; Gastric tubular adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1603 ! NCI-N87
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 19-12-24; Version: 9
//
RX   PubMed=26919099; DOI=10.18632/oncotarget.7575; PMCID=PMC4951299;
RA   Arienti, Chiara
RA   Zanoni, Michele
RA   Pignatta, Sara
RA   Del Rio, Alberto
RA   Carloni, Silvia
RA   Tebaldi, Michela
RA   Tedaldi, Gianluca
RA   Tesei, Anna
RT   "Preclinical evidence of multiple mechanisms underlying trastuzumab
RT   resistance in gastric cancer.";
RL   Oncotarget 7:18424-18439(2016).
//